7月7日,Jasper Therapeutics(杰斯珀治疗公司)的股价暴跌了55%。这家生物技术公司披露,其治疗荨麻疹的实验性疗法在一项研究中部分受试组受到了药物批次问题的影响。这一问题不仅导致了其哮喘开发计划的终止,还可能引发公司裁员。据Jasper公司称,在其针对慢性自发性荨麻疹(CSU)的1b/2a期BEACON研究中,一个药物批次出现了问题,导致两个剂量组的研究结果不可靠。而该批次药物还...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.